Appl. No. 10/772,164 Amdt. dated May 3, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1654

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 39 (canceled).

Claim 40 (currently amended): An antibody covalently attached to a target polypeptide having an amino acid sequence heterologous to the antibody wherein the target polypeptide comprises four cysteine residues which together are capable of specifically reacting with a single biarsenical molecule having the formula:

A polypeptide comprising a carrier polypeptide, or a fragment thereof, and a target amino acid sequence heterologous to the amino acid sequence of the carrier polypeptide wherein the target amino acid sequence comprises one or more cysteines which specifically react with a biarsenical molecule having the following formula

Appl. No. 10/772,164 Amdt. dated May 3, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1654

Claim 41 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein a polypeptide domain comprising the target <u>polypeptide</u> amino acid sequence is covalently attached to <u>a</u> the N-terminus of the <u>antibody earrier polypeptide</u>.

Claim 42 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein a polypeptide domain comprising the target <u>polypeptide</u> amino acid sequence is covalently attached to a the C-terminus of the antibody carrier polypeptide.

Claim 43 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein the antibody <u>earrier polypeptide</u> is divided into a first portion and a second portion and the target polypeptide <u>amino acid sequence</u> is located therebetween.

Claim 44 (currently amended): The <u>antibody polypeptide</u> of claim $\underline{40}$ [[1]], wherein the target <u>polypeptide</u> amino acid sequence comprises four cysteines in an α -helical domain.

Claim 45 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein a polypeptide domain comprising the target <u>polypeptide</u> amino acid sequence comprises an α-helical domain having a -cys-cys-X-Y-cys-cys- sequence, wherein X and Y are amino acids.

Claims 46 to 47 (canceled).

Claim 48 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein the target <u>polypeptide</u> sequence is at least 6 amino acids in length.

Claim 49 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein the target polypeptide sequence is at least 10 amino acids in length.

Appl. No. 10/772,164 Amdt. dated May 3, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1654

Claim 50 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein <u>further</u> the target polypeptide has an N-terminal amino acid which is acetylated.

Claim 51 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein <u>the target polypeptide has a C-terminal amino acid which is amidated.</u>

Claim 52 (currently amended): The <u>antibody polypeptide</u> of claim <u>40</u> [[1]], wherein <u>further</u> the target polypeptide has an N-terminal amino acid which is acetylated and a C-terminal amino acid which is amidated.

Claim 53 (currently amended): The <u>antibody</u> polypeptide of claim 52, wherein the target <u>polypeptide</u> sequence comprises the amino acid sequence of SEQ ID NO:1.

Claim 54 (new): The antibody of claim 40, wherein the antibody and the target polypeptide together form a fusion polypeptide.

Claim 55 (new): The antibody of claim 40, wherein the target polypeptide consists essentially of the peptide of SEQ ID NO:2.